Early Onset Neonatal Sepsis: The Burden of Group B Streptococcal and E. coli Disease Continues
BACKGROUND: Guidelines for prevention of group B streptococcal (GBS) infection have successfully reduced early onset (EO) GBS disease. Study results suggest that Escherichia coli is an important EO pathogen.
OBJECTIVE: To determine EO infection rates, pathogens, morbidity, and mortality in a national network of neonatal centers.
METHODS: Infants with EO infection were identified by prospective surveillance at Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Network centers. Infection was defined by positive culture results for blood and cerebrospinal fluid obtained from infants aged ≤72 hours plus treatment with antibiotic therapy for ≥5 days. Mother and infant characteristics, treatments, and outcomes were studied. Numbers of cases and total live births (LBs) were used to calculate incidence.
RESULTS: Among 396 586 LBs (2006–2009), 389 infants developed EO infection (0.98 cases per 1000 LBs). Infection rates increased with decreasing birth weight. GBS (43%, 0.41 per 1000 LBs) and E coli (29%, 0.28 per 1000 LBs) were most frequently isolated. Most infants with GBS were term (73%); 81% with E coli were preterm. Mothers of 67% of infected term and 58% of infected preterm infants were screened for GBS, and results were positive for 25% of those mothers. Only 76% of mothers with GBS colonization received intrapartum chemoprophylaxis. Although 77% of infected infants required intensive care, 20% of term infants were treated in the normal newborn nursery. Sixteen percent of infected infants died, most commonly with E coli infection (33%).
CONCLUSION: In the era of intrapartum chemoprophylaxis to reduce GBS, rates of EO infection have declined but reflect a continued burden of disease. GBS remains the most frequent pathogen in term infants, and E coli the most significant pathogen in preterm infants. Missed opportunities for GBS prevention continue. Prevention of E coli sepsis, especially among preterm infants, remains a challenge.
WHAT'S KNOWN ON THIS SUBJECT:
Early onset neonatal sepsis causes serious morbidity and mortality in newborns. Substantial disease reduction has occurred with intrapartum antibiotic prophylaxis treatment of at-risk women to reduce vertical transmission of early onset group B streptococcal disease. Predominant neonatal pathogens are thought to change over time.
WHAT THIS STUDY ADDS:
In a national cohort of ∼400 000 infants, rates of early onset sepsis were 0.98 cases per 1000 live births. Infection rates increased with decreasing gestational age and birth weight. The most frequent pathogens were group B streptococci (GBS) in term infants and Escherichia coli in preterm infants. Opportunities for GBS prevention continue to be missed.
Early onset sepsis (EOS) in neonates continues to be a serious and feared complication. In the 1970s, group B streptococcal (GBS) infections emerged as the leading cause of EOS and meningitis.1 Prevention strategies based on intrapartum chemoprophylaxis to reduce vertical transmission of invasive GBS disease in at-risk women resulted in substantial reduction in early onset GBS disease.2,3 In 2002, the Centers for Disease Control and Prevention (CDC) recommended universal antenatal screening at 35 to 37 weeks of pregnancy and intrapartum chemoprophylaxis for women with GBS colonization.4 An additional reduction in invasive GBS disease was reported after publication of these revised guidelines.5,6
The epidemiology of neonatal sepsis is a changing landscape.7,8 In the past decade, several studies revealed increasing rates of early onset Escherichia coli sepsis, particularly among preterm infants.9,–,14 With widespread use of maternal intrapartum antibiotics (∼30% of women in the United States receive intrapartum antibiotics for GBS prevention),15 concerns have been raised about the potential for increased risk of non-GBS EOS. Because results of several studies demonstrated increased severity of disease and risk of death for newborns with Gram-negative infections, such a change would be particularly alarming.9,16,–,18 Continued surveillance to monitor changes in pathogens, disease severity, and outcome is important as we consider optimal prevention and treatment strategies. In this study we investigated the epidemiology of EO infection among all infants born at centers of the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Neonatal Research Network (NRN) during a 4- year period, a cohort of ∼400 000 live births (LBs).
Prospective surveillance for EOS and EO meningitis (EOM) was conducted among live-born infants of all gestational ages (GAs) with birth weights (BWs) >400 g who were delivered at 1 of 16 university-based neonatal centers during the period from February 1, 2006, to December 31, 2009. EOS and EOM were defined by isolation of a pathogen from blood or cerebrospinal fluid (CSF) culture of samples drawn within 72 hours of birth and antibiotic treatment for ≥5 days (or death at <5 days while receiving antibiotic therapy). Early onset infection included EOS and/or EOM as defined above. Cases were identified by research-team review of patient, microbiology, and hospital epidemiology records.
Detailed maternal intrapartum and newborn information was collected, including data on maternal GBS screening, intrapartum antibiotic use within 72 hours of delivery, clinical and histologic chorioamnionitis, and maternal risk factors for EO GBS, such as a previous infant with GBS infection, GBS bacteriuria, intrapartum fever (≥38.0°C), delivery at <37 weeks, and rupture of membranes (ROM)≥18 hours before delivery. Neonatal information included infecting organism, antibiotic therapy, severity of illness, and outcome (death, discharge from hospital). Antibiotic susceptibility data were collected if available.
Coagulase-negative staphylococci (CoNS), micrococci, propionibacteria, corynebacteria, or diphtheroids grown alone in a single culture were considered contaminants, regardless of site determination of contaminant status. Cultures that grew more than 1 organism were considered contaminants on the basis of the attending physician's judgment and decision to discontinue antibiotics before day 5 in a surviving infant. Infants were classified as “symptomatic” if they required blood pressure support at ≤72 hours of age or had respiratory distress, apnea, neutropenia (absolute neutrophil count < 1000/mm3) or thrombocytopenia (platelet count < 100 000/μL).
Maternal and infant characteristics, antibiotic use, and clinical outcomes were examined overall and between infants with E coli and GBS. Statistical significance for unadjusted comparisons was determined by Fisher's exact or χ2 tests (categorical variables) and the Kruskal-Wallis test (continuous variables). Comparisons adjusted for GA were made by using linear or logistic regression models with statistical significance determined by F or Wald χ2 tests. The adjusted relative risk of death and reported 95% confidence intervals were based on parameter and variance estimates from a Poisson regression model with robust variance estimators.19 Models used data from all infants with EO infection and included GA (continuous) and a pathogen-group indicator, which allowed for comparison of infants with E coli and GBS. Infection rates were determined by the number of infants with EOS/EOM divided by the total number of LBs of infants with a BW of >400 g during the study period. BW-specific rates were calculated by using the number of infants with EO infection among LBs according to BW group (401–1500 g, 1501–2500 g, and >2500 g).
Between February 1, 2006, and December 31, 2009, 611 infants with positive cultures of samples obtained at ≤72 hours of age were identified among 396 586 infants born at NRN hospitals. A single culture with CoNS was obtained for 149 infants (142 blood cultures and 7 CSF cultures). Some centers considered all CoNS true infections, whereas others considered them all contaminants (range for “true” infections excluding 0% and 100%: 14%–67%). Because of striking differences in interpretation, infants for whom a single culture was positive for CoNS were excluded from analysis. Overall, 222 infants had an organism found in culture that was considered a contaminant and were excluded from additional analyses. EOS and/or EOM were diagnosed in 389 infants, of whom 199 (51%) were preterm (22–36 weeks' GA) and 190 (49%) were term (37+ weeks' GA).
Pathogens and Infection Rates
The most frequent EO pathogen was GBS (43%), followed by E coli (29%) (Table 1). Infection with Staphylococcus aureus was infrequent; only 1 infant with methicillin-resistant S aureus in blood was identified. No infections with vancomycin-resistant enterococci were identified. Thirteen infants had polymicrobial infections (12 in blood and 1 in CSF). Incidence of EO infection was 0.98 cases per 1000 LBs (range across centers: 0.33–2.44 cases per 1000 LBs). Incidence was highest among infants with a BW of 401 to 1500 g and lowest among those with a BW of >2500 g (Table 2). The overall incidence of infection with GBS (0.41 per 1000 LBs) was higher than E coli (0.28 per 1000 LBs). Rates of E coli infection were higher than rates of GBS among very low birth weight (VLBW) infants (5.09 vs 2.08 per 1000 LBs) and infants with a BW of 1501 to 2500 g (0.54 vs 0.38 per 1000 LBs). Among infants with a BW of >2500 g, GBS rates were higher than E coli rates (0.35 vs 0.07 per 1000 LBs).
All infants with EO infection had at least 1 blood culture performed (20% had 1 blood culture; 47% had 2 blood cultures;, 33% had ≥3 blood cultures), and 70% had a lumbar puncture (LP) performed. Likelihood of an LP increased with increasing BW (401–1500: 47%; 1501–2500 g: 71%; >2500 g: 86%). Only 17 of 389 infants (4%; 6% of those with LP) had a pathogen isolated from CSF; 7 of these infants had a negative blood culture (2% of all infants; 3 of 7 mothers received intrapartum antibiotics). E coli was the most frequently isolated CSF pathogen and was always associated with E coli in blood. Most infants (76%) were started on antibiotics before their LP, with ∼1 day between blood and CSF cultures.
All GBS isolates tested were sensitive to penicillin (93 tested), ampicillin (20 tested), and vancomycin (49 tested); however, 46% were resistant to erythromycin (63 tested) and 20% to clindamycin (46 tested). Among E coli isolates tested, 78% of 102 were ampicillin resistant, 4% of 103 were gentamicin resistant, and 3% of 94 were resistant to third-generation cephalosporins. One E coli isolate resistant to third-generation cephalosporins was reported to be an extended-spectrum β-lactamase producer. Ampicillin resistance was not more likely among infants whose mothers received intrapartum ampicillin (85%) than among those who did not (69%; P = .085). Susceptibility results were available for 2 of the 3 infants with CoNS; both were sensitive to vancomycin and gentamicin.
Infant Antibiotic Therapy
The majority of infants with infections (82%) received ampicillin and gentamicin only for presumed early infection. EOM was diagnosed in only 17 patients, and they were more likely to be started on ampicillin, gentamicin, and cefotaxime as empiric antibiotic therapy, compared with infants with EOS, (24% vs 4%; P = .008). Small numbers of infants were started on other combinations of antibiotics. After pathogen and susceptibility identification, antibiotics were changed for 44% infants. Vancomycin, cefotaxime, and penicillin were the antibiotics most frequently added. Among 160 infants with GBS, the majority (73%) continued on ampicillin once culture results were available; 17% were switched to penicillin with or without continuation of gentamicin. Among 107 infants with E coli infections, 36% had initial antibiotic therapy continued while 46% had cephalosporins added. Among 3 infants with >1 blood culture positive for CoNS, 2 had vancomycin added to their empiric therapy. The third infant whose isolate was sensitive to gentamicin remained on gentamicin.
Maternal Intrapartum Antibiotics and GBS Screening
Overall, 53% of women who delivered infants with EOS received intrapartum antibiotics (preterm 69% versus term 36%). The proportion of mothers who received antibiotics increased with increasing duration between admission and delivery: <4 hours, 37%; 4 to 24 hours, 46%; >24 hours, 66%; P < .001. Suspected chorioamnionitis (46%), ROM < 37 weeks' GA (40%), fever (28%), and GBS prophylaxis (25%) were the most common reasons for intrapartum antibiotics, with multiple reasons given more than half the time. When antibiotics were ordered for suspected chorioamnionitis with or without fever, ampicillin (76%) and gentamicin (71%) were most frequently given. Ampicillin (77%) and erythromycin (46%) were the most frequently administered antibiotics for ROM < 37 weeks' GA. GBS prophylaxis alone was the reason for administration of intrapartum antibiotics for 33 of 205 mothers who received antibiotics, with penicillin (52%) and ampicillin (30%) most commonly received.
Despite CDC recommendations for universal antenatal screening for GBS, only 67% of mothers who delivered term infants who had infections were screened; screening was less common among women who delivered preterm infants who had infections (58%). Among those screened, 25% were colonized with GBS (Table 3). Of mothers whose infants developed EO GBS, 58% were screened (63% term, 44% preterm). The GBS screening culture was negative for mothers of 81% of term and 26% of preterm infants with EO GBS, which reflects either a false-negative screen or a change in colonization status. Only 76% of mothers with GBS bacteriuria, 76% with a positive GBS screen, and 66% with unknown GBS colonization status and a risk factor (gestation < 37 weeks, ROM ≥ 18 hours before delivery, maternal temperature ≥38.0°C) received intrapartum antibiotics.
Patient Characteristics, Clinical Care, Outcome: GBS Versus E coli Infections
The majority of infants with GBS were term (73%), whereas the majority with E coli were preterm (81%). Infants infected with GBS were more likely than infants with E coli to be black (52% vs 29%, Table 4). A greater proportion of mothers of infants with EO E coli infection received antibiotics within 72 hours of delivery compared with mothers of infants with GBS (79% vs 38%, adjusted P < .001).
Chorioamnionitis was more frequently documented in the medical record for mothers of infants with E coli than mothers with GBS infections (56% vs 33% overall; adjusted P = .02, Table 4). Placental pathology analysis was performed for a greater proportion of infants with E coli than GBS (81% vs 52%; adjusted P = .03). Among 154 women with documented chorioamnionitis, 82% had placental pathology analysis performed, with histologic chorioamnionitis confirmed for 90%. No difference in the occurrence of histologic chorioamnionitis was detected among infants with GBS or E coli.
Most infants with EO infection (77%) required intensive care (95% preterm, 58% term infants). However, 20% of infected term infants seemed healthy (blood culture performed for maternal risk factors) and received care in the normal newborn nursery. Given that more infants with E coli were preterm, it is not surprising that a higher proportion received intensive care (93%) compared with infants with GBS (66%, Table 5). Among infants who received intensive/intermediate care, greater proportions of those with E coli than with GBS had apnea and received blood pressure support, although differences for all except volume expansion were no longer statistically significant after adjustment for GA. Thrombocytopenia was more common among infants with E coli than infants with GBS.
Although most infants with EOS/EOM survived to discharge, 16% died; 57% deaths were in the first 3 days of life (Table 6). The case fatality rate was inversely related to GA (22–24 weeks: 54%; 25–28 weeks: 30%; 29–33 weeks: 12%; 34–36 weeks: 0%; ≥37 weeks: 3%). More infants with E coli than with GBS infection died (33% vs 9%; P < .001). However, after adjustment for GA, the risk of death was not significantly higher for infants with E coli compared with GBS (adjusted relative risk: 1.27; 95% confidence interval: 0.77–2.08). Preterm infants with E coli were more likely to have a fulminant illness with death in the first 3 days of life (64% of those who died).
This prospective surveillance study of almost 400 000 live births documents that in the era of intrapartum chemoprophylaxis, the overall rate of EO infection is low (0.98 per 1000 live births), with the highest rates among the most premature infants. During the 4 year study period, no significant changes were found in the overall rate of EOS or in rates of infection with GBS or E coli, the most frequent pathogens responsible for EOS. GBS remains the most frequent EO pathogen, especially for term infants. With ∼4.3 million live births in the United States each year, these rates (adjusted for birth weight) reflect an estimated 3306 newborns with EO infection annually and ∼344 neonatal deaths (∼1619 cases and 88 deaths with GBS and 751 cases and 194 deaths with E coli), and reveal a continuing burden of disease with morbidity and mortality.
Missed opportunities for prevention of GBS were identified, including failure to screen all women who deliver at term, failure to provide antibiotics to all colonized women or to those who delivered preterm with unknown colonization status, and false-negative GBS screens among some women who deliver infants with GBS infection. Negative GBS screens among women who deliver infants with GBS are particularly troubling and may be attributable to insufficient sampling, delay in processing, suboptimal laboratory techniques, recent antibiotic use, or colonization after screening was performed. Point-of-care diagnostics, ie, accurate rapid GBS diagnostic tests at the time a woman presents in labor, would help reduce the number of colonized women who remain undetected and therefore untreated and would further reduce EO GBS cases. Of note, the recently updated CDC GBS prevention guidelines20 recommend chemoprophylaxis for women with risk factors at delivery, despite negative screening cultures.
Several studies have revealed increased rates of E coli infection among preterm infants.8,9 The results of our study, conducted in a large and geographically diverse population, establish that E coli has become the most frequent EOS pathogen among preterm infants and that preterm infants with E coli infection are at highest risk of severe disease and death. The NICHD NRN has been studying infections among VLBW infants for almost 2 decades. A major shift in EOS pathogen distribution among VLBW infants was identified at NRN sites in the late 1990s (reduction in GBS and increase in E coli).9,13 Although the results of the current study confirm these earlier observations, it is reassuring that the incidence of E coli among VLBW infants at NRN sites has not continued to increase and E coli has not emerged as a frequent EO pathogen among term infants. Our data suggest that widespread use of intrapartum antibiotic prophylaxis to reduce vertical transmission of GBS has not resulted in a further increase in non-GBS EO sepsis among the larger cohort of infants of all BWs or among VLBW infants beyond that noted previously. Prevention strategies for EO E coli disease need to be developed and implemented. Analysis of risk factors associated with EO E coli (as was done with GBS) could help identify high risk women to target for prevention. Our data suggest that severe manifestations of clinical chorioamnionitis (uterine tenderness, foul-smelling amniotic fluid) may be markers for increased risk of E coli infection and warrant broad spectrum antibiotic therapy in the mother and infant.
Strengths of this study include the size of the NRN and the detailed information collected prospectively, including clinical data collection beyond the scope of most surveillance systems. Although the NRN is a large and diverse national network of academic centers and we reviewed infection status of almost 400 000 LBs, this is not a population-based nationally representative cohort. Other limitations include review of case data only, without an uninfected comparison group to assess risk factors and GBS prevention strategies more broadly. EO infection was defined by positive cultures. Because of widespread use of intrapartum antibiotics, some infants with true, but culture-negative infection would not have been identified in this study, a limitation of all studies that base EOS rates on newborn blood culture results.
Bacteremia is a known risk factor for neonatal meningitis.21,–,23 In our cohort, only two-thirds of infants with EOS underwent an LP. More term infants underwent an LP, in large part because preterm infants are often considered too unstable to tolerate an LP. Although most CSF cultures were negative, 76% of infants had their LP performed after antibiotics had been initiated, which may have sterilized their CSF and made meningitis more difficult to diagnose. Although the number of infants with a positive CSF culture and a negative blood culture was low, these cases are a reminder that meningitis will be missed in some infants if an LP is not part of the sepsis workup.23 Moreover, antibiotic therapy may change with EOM caused by Gram-negative organisms.
The importance of CoNS as EOS pathogens remains unclear. Although 149 infants had a single early culture that was positive for CoNS, more than half of these were judged to be contaminants by the reporting study center, with wide center variability in assessment of a single positive blood culture. Only 3 infants had >1 positive CoNS culture and what was considered to be a true infection. Prospective studies to investigate the vaginal ecology of pregnant women and the vertical transmission of CoNS, as well as continued surveillance for these organisms among newborns with EOS, will help determine if CoNS are emerging as important EO pathogens.
Rational choice of antibiotics for the infant with presumed infection requires review of antibiotic susceptibility of the predominant organisms that cause disease at the local level.24 Treatment of the infected infant must be based on antibiotic susceptibility of the infecting organism and clinical outcome. Ampicillin and gentamicin continue to be the recommended empiric antibiotics for the infant at risk for EOS.25 Our study results support this recommendation, because all GBS isolates tested were sensitive to ampicillin and 96% of E coli isolates tested were sensitive to gentamicin.
With neonatal intensive care, the vast majority of infants with EOS survive. The most immature infants remain at highest risk of death. Although some investigators have reported higher mortality for infants infected with Gram-negative agents, after we adjusted for GA we did not find a statistically significant increase in the risk of death for infants infected with E coli versus GBS. Although improved treatment strategies may reduce the current 16% mortality, strategies to reduce the unacceptably high rates of preterm birth in the United States are more likely to reduce deaths associated with early onset infections, as well as deaths related to other complications of prematurity.
This study was supported in part by PHS grant UL1 RR025008 from the Clinical and Translational Science Award program, National Institutes of Health, National Center for Research Resources. The National Institutes of Health, the NICHD, and the Centers for Disease Control and Prevention provided grant support for the Neonatal Research Network's Early Onset Sepsis Study. Data collected at participating sites of the NICHD NRN were transmitted to RTI International, the data coordinating center (DCC) for the network, which stored, managed, and analyzed the data for this study. On behalf of the NRN, Dr Abhik Das (DCC Principal Investigator), and Ms Nellie Hansen (DCC Statistician) had full access to all the data in the study and take responsibility for the integrity of the data and accuracy of the data analysis.
The following investigators, in addition to those listed as authors, participated in this study: NRN Steering Committee Chair: Michael S. Caplan, MD, University of Chicago, Pritzker School of Medicine; Case Western Reserve University Rainbow Babies & Children's Hospital (GCRC M01 RR80, U10 HD21364): Avroy A. Fanaroff, MD, Nancy S. Newman, BA, RN; CDC (IAA 05FED32885-00): Stephanie J. Schrag, DPhil; Cincinnati Children's Hospital Medical Center, University of Cincinnati Hospital, and Good Samaritan Hospital (GCRC M01 RR8084, U10 HD27853): Edward F. Donovan, MD, Kate Bridges, MD, Barbara Alexander, RN, Cathy Grisby, BSN, CCRC, Holly L. Mincey, RN, BSN, Jody Hessling, RN; Duke University School of Medicine University Hospital, Alamance Regional Medical Center, and Durham Regional Hospital (GCRC M01 RR30, U10 HD40492): C. Michael Cotten, MD, MHS, Kathy J. Auten, MSHS, Kimberly A. Fisher, PhD, FNP-BC, IBCLC, Katherine A. Foy, RN; Emory University Children's Health Care of Atlanta, Grady Memorial Hospital, and Emory Crawford Long Hospital (U10 HD27851, 5P20RR11104): David P. Carlton, MD, Ann M. Blackwelder, RNC, BS, MS; NICHD: Stephanie Wilson Archer, MA; Indiana University, Indiana University Hospital, Methodist Hospital, Riley Hospital for Children, and Wishard Health Services (GCRC M01 RR750, U10 HD27856): Dianne E. Herron, RN, Leslie Dawn Wilson, BSN, CCRC; RTI International (U01 HD36790): W. Kenneth Poole, PhD, Jeanette O'Donnell Auman, BS, Margaret Cunningham, BS, Carolyn Petrie Huitema, MS, Kristin M. Zaterka-Baxter, RN, BSN; Stanford University Dominican Hospital, El Camino Hospital, and Lucile Packard Children's Hospital (GCRC M01 RR70, U10 HD27880): David K. Stevenson, MD, Marian M. Adams, MD, Magdy Ismail, MD, MPH, M. Bethany Ball, BS, CCRC, Andrew W. Palmquist, RN, Melinda S. Proud, RCP; Tufts Medical Center Floating Hospital for Children (GCRC M01 RR54, U10 HD53119): Brenda L. MacKinnon, RNC, Ellen Nylen, RN, BSN; University of Alabama at Birmingham Health System and Children's Hospital of Alabama (GCRC M01 RR32, U10 HD34216): Namasivayam Ambalavanan, MD, Monica V. Collins, RN, BSN, MAEd, Shirley S. Cosby, RN, BSN; University of Iowa Children's Hospital (GCRC M01 RR59, U10 HD53109): John A. Widness, MD, Karen J. Johnson, RN, BSN; University of New Mexico Health Sciences Center (GCRC M01 RR997, U10 HD53089): Conra Backstrom Lacy, RN, Rebecca Montman, BSN; University of Texas Southwestern Medical Center at Dallas Parkland Health & Hospital System and Children's Medical Center Dallas (GCRC M01 RR633, U10 HD40689): Charles R. Rosenfeld, MD, Walid A. Salhab, MD, Gaynelle Hensley, RN, Melissa H. Leps, RN, Nancy A. Miller, RN, Alicia Guzman; University of Texas Health Science Center at Houston Medical School, Children's Memorial Hermann Hospital, and Lyndon Baines Johnson General Hospital/Harris County Hospital District (U10 HD21373): Kathleen A. Kennedy, MD, MPH, Georgia E. McDavid, RN, Patti L. Tate, RCP, Sharon L. Wright, MT; University of Utah University Hospital, LDS Hospital, and Primary Children's Medical Center (CTSA UL1 RR25764, GCRC M01 RR64, U10 HD53124): Bradley A. Yoder, MD, Karen A. Osborne, RN, BSN, CCRC, Jennifer J. Jensen, RN, BSN, Cynthia Spencer, RNC, Kimberlee Weaver-Lewis, RN, BSN; Wayne State University Hutzel Women's Hospital and Children's Hospital of Michigan (U10 HD21385), Rebecca Bara, RN, BSN; Women & Infants' Hospital of Rhode Island, Warren Alpert Medical School at Brown University (U10 HD27904): William Oh, MD, Angelita M. Hensman, RN, BSN; Yale University Yale-New Haven Children's Hospital and Bridgeport Hospital (CTSA UL1 RR24139, GCRC MO1 RR125, GCRC M01 RR6022, U10 HD27871): Richard A. Ehrenkranz, MD, Harris Jacobs, MD, Patricia Cervone, RN, Monica Konstantino, RN, BSN, JoAnn Poulsen, RN, Janet Taft, RN, BSN.
We are indebted to our medical and nursing colleagues and the infants and their parents who agreed to take part in this study. We thank Dr Jennifer Verani for technical advice regarding GBS guidelines and Ms Mazie Tinsley for manuscript preparation.
- Accepted January 11, 2011.
- Address correspondence to Barbara J. Stoll, MD, Department of Pediatrics, Emory University School of Medicine, and Children's Healthcare of Atlanta, 2015 Uppergate Drive, Atlanta, GA. E-mail:
FINANCIAL DISCLOSURE: The authors have indicated they have no financial relationships relevant to this article to disclose.
Funded by the National Institutes of Health (NIH).
- Bizzarro MJ,
- Raskind C,
- Baltimore RS,
- Gallagher PG
- Bizzarro MJ,
- Dembry L-M,
- Baltimore RS,
- Gallagher PG
- Daley AJ,
- Isaacs D
- Stoll BJ,
- Hansen NI,
- Higgins RD,
- et al
- Schrag SJ,
- Hadler JL,
- Arnold KE,
- Martell-Cleary P,
- Reingold A,
- Schuchat A
- Karlowicz MG,
- Buescher ES,
- Surka AE
- Zou G
- Verani JR,
- McGee L,
- Schrag SJ
- Stoll BJ,
- Hansen N,
- et al
- Garges HP,
- Moody A,
- Cotten CM,
- et al
- Pickering LK,
- Baker CJ,
- Kimberlin DW,
- Long SS
- Copyright © 2011 by the American Academy of Pediatrics